[Radio] Gene Editing for Individuals and their Families and Family Caregivers
By Gordon Atherley,
Voice America
| 03. 01. 2016
[an interview with CGS's Marcy Darnovsky]
Episode Description
Dr. Marcy Darnovsky is Executive Director of the Center for Genetics and Society, http://www.geneticsandsociety.org/. She describes her career and the Center’s work. She explains human gene editing, the ways it could be used for medical treatment and research, and the pros and cons. She explains germline gene modification and the Center’s position on its benefits and risks. She highlights policies on human germline modification in influential countries and identifies the main differences. She explains why the prospect of human germline modification is so controversial. She says how well she thinks North American would-be parents and family caregivers understand human gene editing and human germline modification, what more she would like to see done to improve understanding of human gene editing and human germline modification, and what more governments should do to improve information flows to parents, would-be parents and family caregivers, researchers, and the medical profession.
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...